Candid Therapeutics

What Candid Therapeutics does

Candid Therapeutics, Inc. is a privately held, clinical-stage biotechnology company founded in 2024 and headquartered in San Diego, California, with additional clinical operations in Shanghai, China. The company develops T-cell engager (TCE) antibody therapeutics — including bispecific (BCMAxCD3, CD20xCD3) and trispecific (CD19xCD20xCD3, BCMAxCD19xCD3) antibodies — that redirect T-cells to selectively eliminate autoreactive B-cells, with the goal of achieving deeper and more durable B-cell depletion than monoclonal antibodies (e.g., Rituxan) while avoiding the lymphodepletion burden and manufacturing cost of cell therapies such as CAR-T. Its four-program pipeline — led by cizutamig (BCMAxCD3) advancing into Phase 2 in myasthenia gravis and interstitial lung disease, and CND261 (CD20xCD3) in Phase 1 across multiple autoimmune indications — has been clinically evaluated in nearly 200 patients across oncology and autoimmune settings spanning more than 10 indications.

Candid is pre-revenue and does not sell a commercial product; the company has been funded entirely through equity financings (US$370M debut Series A in September 2024, plus an oversubscribed US$505M PIPE financing committed alongside a March 2026 reverse merger agreement with Rallybio that was subsequently terminated) and in-licensing arrangements with platform partners including WuXi Biologics, EpimAb Biotherapeutics, Ab Studio, and Nona Biosciences. Its go-to-market motion has been enterprise/out-licensing and investor-relations-driven — presentations at the J.P. Morgan Healthcare Conference, Cantor, BofA Securities, and the World Medical Innovation Forum — culminating in a definitive agreement signed in May 2026 for UCB (Brussels, Belgium) to acquire Candid for up to US$2.2 billion (US$2.0B upfront plus up to US$200M in milestones), expected to close by end of Q2 to early Q3 2026. Post-close, commercialization of any approved TCE products will run through UCB's existing global immunology infrastructure spanning approximately 40 countries.

Name

Candid Therapeutics

Legal name

Candid Therapeutics, Inc.

Website

https://candidrx.com

Company type

Private

Founded year

2024

Operating status

Acquired

Headcount range

11–50 employees

Short description

Candid Therapeutics is a clinical-stage biotechnology company developing bispecific and trispecific T-cell engager antibodies for autoimmune diseases. Founded in 2024 and based in San Diego, it advances a four-program pipeline led by cizutamig and CND261, with commercialization to flow through acquirer UCB.

Ownership category

akta.pro rank

Product category

Autoimmune Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Dendritic Cell & Other APC-based Therapies (HLAAABAF), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• T-cell engager antibodies
• Autoimmune disease therapeutics
• Bispecific antibody therapies
• B-cell depletion therapies
• Clinical-stage biotechnology

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue / Acquisition-based exit: Candid Therapeutics is a clinical-stage, privately held biotechnology company with no commercial product sales. Revenue generation was not pursued as a standalone strategy; the company was acquired by UCB in May 2026 for up to US$2.2 billion (US$2 billion upfront plus up to US$200 million in potential milestone payments), representing an exit for shareholders. Previously, capital was raised through equity financings (US$370M Series A at launch in September 2024) and a planned concurrent private placement of over US$505M tied to a reverse merger with Rallybio (which fell through after the UCB deal). Upfront, milestone, and royalty payments from in-licensing arrangements (e.g., WuXi Biologics entitled to up to US$925M in development and sales milestones plus royalties; EpimAb entitled to over US$1B in milestones plus royalties; Nona Biosciences eligible for up to US$320M) represent contingent milestone-based licensing economics.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Candid Therapeutics develops a pipeline of T-cell engager (TCE) antibody drug candidates — both bispecific and trispecific — designed to redirect T-cells to selectively eliminate autoreactive B-cells and plasma cells for the treatment of autoimmune diseases. Its lead clinical-stage assets are cizutamig (BCMAxCD3) and CND261 (CD20xCD3), with preclinical trispecifics CND319 and CND460 in IND-enabling studies. The company conducts clinical trials across more than 10 autoimmune indications including myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, IgA nephropathy, and interstitial lung disease.

Product overview

Candid Therapeutics is a clinical-stage biotechnology company with a pipeline-plus-modular architecture centered on a T-cell engager (TCE) platform for autoimmune and inflammatory diseases. The core platform applies modular, multi-antigen targeting to redirect T-cells for deep, targeted depletion of pathogenic B-cell populations. Its portfolio comprises four named candidates: lead clinical-stage bispecific cizutamig (BCMAxCD3) advancing into Phase 2 in myasthenia gravis and interstitial lung disease; clinical-stage bispecific CND261 (CD20xCD3) being evaluated across multiple autoimmune indications; and preclinical trispecifics CND319 (CD19xCD20xCD3, in-licensed from WuXi Biologics) and CND460 (BCMAxCD19xCD3). Together these products represent Candid's diversified TCE pipeline targeting different B-cell protein targets and varying depths of B-cell depletion across more than 10 autoimmune indications.

Differentiator

Problem solved

Functional benefit

Products and services

• Cizutamig (BCMAxCD3) Lead clinical-stage bispecific T-cell engager antibody that binds B-cell maturation antigen (BCMA) on B-cells and CD3 on T-cells, enabling T-cell-mediated cytotoxicity against BCMA-expressing B-cells. Designed to maintain cytotoxicity while limiting cytokine release. Currently in Phase 1 across over 10 autoimmune indications, with global Phase 2 studies in myasthenia gravis and interstitial lung disease planned for 2026.
• CND261 (CD20xCD3) Clinical-stage CD20xCD3 bispecific T-cell engager antibody designed to target a broad range of B-cell subtypes from pro B-cells to plasmablasts/plasma cells. Engineered with low CD3 affinity to reduce excessive T-cell activation while maintaining potent and selective B-cell depletion. Dosed in over 110 patients including over 20 with autoimmune diseases, with a favorable safety profile.
• CND319 (CD19xCD20xCD3) Preclinical CD19xCD20xCD3 trispecific T-cell engager antibody designed to target the CD19 and CD20 antigens on a broad range of B-cell subtypes. Currently undergoing IND enabling studies with a promising therapeutic index profile in non-human primate studies; first-in-human studies planned for mid-2026.
• CND460 (BCMAxCD19xCD3) Preclinical BCMAxCD19xCD3 trispecific T-cell engager antibody designed to target the BCMA and CD19 antigens on a broad range of B-cell subtypes, applying a modular multi-antigen targeting strategy to achieve deeper depletion of pathogenic B cells. Currently undergoing IND enabling studies.

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered flagship and core.

• UCBflagshipStrategic or Co-development Partner · 3 May 2026UCB, a global biopharmaceutical company headquartered in Brussels, Belgium, signed a definitive agreement on May 3, 2026 to acquire Candid Therapeutics for up to US$2.2 billion (US$2 billion upfront plus up to US$200 million in potential future milestone payments). The acquisition brings cizutamig and Candid's multispecific TCE pipeline into UCB's immunology pipeline, building on UCB's recently announced transaction with Antengene and reflecting a platform-driven strategy in next generation immunology. Lazard acted as financial advisor to UCB; Covington & Burling LLP as legal counsel. Jefferies LLC and Goldman Sachs & Co. LLC served as joint lead financial advisors to Candid, with BofA Securities also providing financial advice and Cooley LLP as legal counsel to Candid. Expected to close by end of Q2 to early Q3 2026, subject to anti-trust clearance.
• Rallybio CorporationflagshipStrategic or Co-development Partner · 2 March 2026Rallybio Corporation (Nasdaq: RLYB), based in New Haven, Connecticut, entered into a definitive merger agreement with Candid Therapeutics on March 2, 2026, pursuant to which Rallybio would acquire Candid. The combined company would operate as Candid Therapeutics and trade on Nasdaq under ticker symbol 'CDRX'. Concurrent oversubscribed private financing of over US$505 million was committed. Pre-Transaction Rallybio equityholders were expected to own approximately 3.65% and pre-Transaction Candid equityholders approximately 96.35%. Wedbush Securities served as financial advisor and Cooley LLP as legal counsel to Candid; Evercore as lead financial advisor, Citizens Capital Markets & Advisory as co-financial advisor, and Ropes & Gray LLP as legal counsel to Rallybio; Jefferies, BofA Securities, TD Cowen and Cantor Fitzgerald as placement agents. The merger fell through after UCB signed a definitive agreement to acquire Candid for up to US$2.2 billion, with Rallybio receiving a US$50 million termination fee.
• WuXi BiologicscoreStrategic or Co-development Partner · 6 January 2025Candid Therapeutics entered into an agreement with WuXi Biologics under which Candid obtained exclusive global rights to a preclinical trispecific T-cell Engager (CND319 / CD19xCD20xCD3) discovered at WuXi Biologics' proprietary universal multispecific antibody platform WuXiBody™. Candid plans to complete IND enabling studies to enable first-in-human studies in the first half of 2026. Under the terms of the agreement, WuXi Biologics is entitled to obtain an upfront payment, and development and sales milestones totaling up to US$925 million as well as royalties. WuXi Biologics is a leading global CRDMO (stock code: 2269.HK).
• EpimAb BiotherapeuticscoreStrategic or Co-development Partner · 16 December 2024Candid Therapeutics entered a strategic research collaboration with EpimAb Biotherapeutics to discover and develop novel T-Cell Engager program candidates for various autoimmune indications. EpimAb is a clinical-stage biopharmaceutical company specializing in multi-specific antibodies using its proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms. Under the terms, EpimAb is entitled to obtain an upfront payment, and development and sales milestones totaling over US$1 billion (assuming multiple drug candidates advance through commercialization), as well as royalties on net sales. Candid holds exclusive worldwide rights to develop and commercialize programs discovered under the collaboration.
• Ab StudiocoreStrategic or Co-development Partner · 16 December 2024Candid Therapeutics and Ab Studio entered a strategic research collaboration to discover and develop novel T Cell Engager program candidates for various autoimmune indications. Ab Studio is a US biotech based in the San Francisco Bay Area focused on the discovery of novel antibodies via computer-aided design. Notably, one of Candid's clinical stage programs, CND261 (CD20xCD3), was originally designed by Ab Studio. Under the terms, Ab Studio will receive undisclosed payments and Candid holds exclusive rights to develop and commercialize programs discovered under the collaboration.
• Nona BiosciencescoreStrategic or Co-development Partner · 16 December 2024Nona Biosciences (Cambridge, MA) announced a research collaboration and license agreement with Candid Therapeutics to discover next-generation T-cell engagers using Nona's proprietary HBICE® technology platform. Nona is a global biotechnology company providing a total solution from 'Idea to IND' (I to ITM), leveraging its Harbour Mice® platforms. Under the terms, Nona Biosciences is eligible to receive up to US$320 million, including an upfront payment and potential milestone payments. Candid is responsible for all further product development.
• Cooley LLPcoreOthers · 9 September 2024Cooley LLP advised Candid Therapeutics on its US$370 million debut capital raise, the three-way merger with Vignette Bio and TRC 2004, and the UCB acquisition transaction. Cooley has previously supported Candid's management team in prior successful transactions (e.g., RayzeBio).

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• UCB: Brussels-based global biopharmaceutical company and Candid's acquirer, with a major immunology franchise including Rystiggo (rozanolixizumab, anti-FcRn for gMG) and zilucoplan (complement C5 inhibitor for gMG). Strategic acquirer of and incumbent in the same autoimmune TCE/bispecific space Candid operates in.
• AbbVie: Global immunology leader with blockbuster franchises Skyrizi (risankizumab) and Rinvoq (upadacitinib) across psoriasis, IBD, RA, and other autoimmune indications. Sets the standard-of-care bar that any novel B-cell-depleting TCE like cizutamig must displace in RA and other rheumatologic diseases.
• Bristol-Myers Squibb: Global biopharmaceutical company with a deep immunology portfolio (Sotyktu/deucravacitinib, Zeposia/ozanimod, Otezla/apremilast) and the acquirer of RayzeBio (Candid CEO Ken Song's prior company, $4.1B deal). Competes for the same autoimmune patient population and has historically acquired innovative immunology platforms.
• Argenx: Global immunology leader whose lead asset efgartigimod (Vyvgart) is an FcRn antagonist approved for generalized myasthenia gravis and CIDP, with active label-expansion into additional autoimmune indications. Most advanced competing mechanism for refractory autoimmune disease patients that Candid's TCE platform also targets.
• Roche: Global biopharmaceutical company with a leading autoimmune franchise (Ocrevus/ocrelizumab for MS, Actemra) and a major bispecific T-cell engager platform (e.g., Lunsumio/mosunetuzumab, Columvi/glofitamab) — directly relevant to Candid's B-cell-targeting TCE mechanism and one of the most credible competitors in deep B-cell depletion.
• Eli Lilly: Global biopharmaceutical company and acquirer of DICE Therapeutics (where Candid CMO/CSO Tim Lu previously served as CMO). Has Taltz (ixekizumab) and active immunology development programs; a repeat buyer of autoimmune platforms that compete with Candid's TCE pipeline.

Direct peers

• Cabaletta Bio: Clinical-stage biotech developing CAR-T cell therapies (e.g., CABA-201, a CD19-CAR-T) for autoimmune diseases including lupus, myositis, and systemic sclerosis. Direct competitor pursuing deep B-cell depletion in autoimmune indications that overlap with Candid's pipeline.
• Kyverna Therapeutics: Clinical-stage cell therapy company developing CD19-directed CAR-T therapies (e.g., KYV-101) for autoimmune diseases including myasthenia gravis, lupus, and stiff person syndrome. Closest direct competitor to Candid's deep B-cell depletion thesis in autoimmune disease via a different modality (CAR-T vs. TCE bispecifics).
• Cartesian Therapeutics: Clinical-stage cell therapy company developing RNA-engineered CAR-T (e.g., Descartes-08 for myasthenia gravis, Descartes-25) and other immunomodulatory therapies for autoimmune disease. Competes for the same deep B-cell depletion narrative in MG and other autoimmune indications as Candid's TCE platform.

Emerging players

• Immunovant: Clinical-stage immunology company developing FcRn-targeted antibodies (batoclimab and next-gen IMVT-1402) for multiple autoimmune indications including myasthenia gravis, Graves' disease, CIDP, and warm autoimmune hemolytic anemia. Competes with Candid in MG and broader autoimmune B-cell-driven disease states.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/candidrx

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Candid Therapeutics